If approved, TLX250-CDx will become the first commercially available imaging agent to accurately and non-invasively diagnose and characterize clear cell renal cell carcinoma (ccRCC), the most common ...
Big cost cuts at Woolworths couldn’t turn investor sentiment around, Flight Centre loses altitude and Westfield owner Scentre ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback